| Measure Type | High Priority Measure? | Collection Type(s) |
|---|---|---|
| Process | yes | MIPS CQM |
Measure Description
Percentage of adult patients (aged 18 or over) with metastatic colorectal cancer and RAS (KRAS or NRAS) gene mutation spared treatment with anti-EGFR monoclonal antibodies